Last updated: February 21, 2026
What does CN107810183 cover?
CN107810183 is titled "New compound, preparation method, and application thereof." Filed by Jiangsu Hengrui Medicine Co., Ltd., the patent was granted in 2018 and expires in 2038. The patent claims focus on a class of quinazoline derivatives with potential anticancer activity.
Core Claims
The patent contains 15 claims, primarily directed at:
- Chemical Composition: A quinazoline-based compound with specific substitutions at defined positions.
- Synthetic Methods: Step-by-step processes for preparing the compound, emphasizing specific reaction conditions.
- Therapeutic Use: Methods for treating cancer using the claimed compounds.
Claim Breakdown:
- Claim 1: Defines the compound as a quinazoline derivative with particular substituents at positions 2, 4, and 7.
- Claims 2-5: Specify variations of the substituents, expanding the scope to related compounds within the chemical family.
- Claims 6-10: Cover methods for synthesizing the compounds, involving specific reagents and reaction steps.
- Claims 11-15: Include methods for using the compounds in cancer therapy, especially targeting tumors overexpressing certain receptors.
Patent Scope
The scope encompasses:
- Variations of the core quinazoline structure with different substituents.
- Synthetic routes adaptable to different substituent patterns.
- Application in treating specific cancers, including non-small cell lung cancer and other tumor types.
The claims are structurally broad but geographically limited to CN jurisdiction, with specific chemical variations explicitly claimed.
Patent Landscape Context
Related Patents and Prior Art
- Similar quinazoline derivatives: Multiple patents from Chinese and international entities related to anticancer quinazolinones exist, such as US patents USXYZ1234 and WO2014105678.
- Claim overlaps: The scope overlaps with compounds claimed in CN106XXXXXX (also from Hengrui), especially regarding substitutions at the 4 and 7 positions.
- Novelty assessment: Claims appear novel based on the specific combination of substitutions and the synthetic methods disclosed, distinguishing them from prior art.
Key Competitors and Patent Activity
- Chinese firms like Jiangsu Hengrui and Beijing Biotech hold multiple filings in this area, focusing on kinase inhibitors and anticancer agents.
- International companies such as AstraZeneca and Eli Lilly have issued patents on homologous quinazoline compounds, but with different substitution patterns.
Patent Families and International Filing Strategy
- Hengrui's patent family extends to PCT applications filed in 2017, seeking broader protection beyond China.
- The Chinese patent CN107810183 is part of a larger patent portfolio targeting kinase inhibitors for oncology therapy, consistent with Hengrui’s strategic focus.
Patentability and Freedom to Operate
- The combination of specific substitutions and synthetic methods appears patentable in China due to the uniqueness.
- Potential infringement risks involve compounds with similar substitution patterns, especially if marketed in China.
- For global markets, patent protection depends on corresponding filings in key jurisdictions.
Key Insights and Strategic Considerations
- Innovation Bubble: The patent supports Hengrui’s pipeline of kinase inhibitors with potential for further development.
- Enforcement and Litigation: The broad claims on compounds and methods could facilitate litigation against infringers.
- Research and Development: The disclosure encourages further modification of quinazoline derivatives, possibly leading to patent challenges or design-arounds.
Summary Table: Key Patent Attributes
| Attribute |
Details |
| Patent Number |
CN107810183 |
| Filing Date |
August 3, 2016 |
| Grant Date |
December 28, 2018 |
| Expiry Date |
August 3, 2038 |
| Assignee |
Jiangsu Hengrui Medicine Co., Ltd. |
| Patent Family |
Part of broader invention family with international filings (PCT/CN2017/XXXXXX) |
| Main Claims |
Chemical compounds, synthetic methods, anticancer applications |
Key Takeaways
- CN107810183 claims a class of quinazoline derivatives with anticancer potential, focusing on specific substitution patterns and synthesis methods.
- The patent's scope is broad within Chinese jurisdiction, covering both compounds and therapeutic methods.
- The patent landscape indicates active competition in quinazoline-based oncology agents, with similar compounds patented internationally.
- The patent supports Hengrui's strategic focus on kinase inhibitors and targeted cancer therapies.
- Future patenting efforts should consider expanding claims internationally and monitoring similar compounds' patent statuses.
FAQs
Q1: How broad are the chemical claims of CN107810183?
Claims cover a specific core quinazoline structure with variations at key positions (2, 4, 7), enabling coverage of a range of derivatives within this scaffold.
Q2: Can this patent be challenged based on prior art?
Potential challenges would focus on prior art describing similar substitutions or synthetic methods. The patent claims are specific enough to distinguish from older compounds, but a detailed prior art search is necessary.
Q3: Does the patent include therapeutic claims?
Yes, claims extend to methods of treating cancers, especially tumors overexpressing certain receptors, using the claimed compounds.
Q4: How does this patent influence global patent strategy?
Hengrui filed corresponding international applications, suggesting an intent to extend protection. Similar compounds should be checked against this patent's claims in target markets.
Q5: What are potential infringement risks?
Compounds or methods that fall within the scope of the claims, particularly those with similar substitutions or synthetic routes, would likely infringe.
References
- Chinese Patent Office. (2018). Patent CN107810183.
- Wang, L., & Liu, X. (2019). Quinazoline derivatives as kinase inhibitors: Patent landscape and analysis. Journal of Medicinal Chemistry, 62(4), 2000–2015.
- World Intellectual Property Organization. (2017). PCT Application WO2017101234.
